Decoy Therapeutics Q1 net loss widens to $2.22 million

Decoy Therapeutics Inc.

Decoy Therapeutics Inc.

DCOY

0.00
  • Decoy Therapeutics posted a net loss of USD 2.22 million, widening from USD 1.71 million a year earlier.
  • Research and development expenses more than doubled to 749,813, driven mainly by the November 2025 merger and addition of the IMP3ACT (Designable Multi-Antivirals) program.
  • General and administrative costs edged down to USD 1.53 million from USD 1.64 million, while interest income and other rose to 59,111 from 9,162.
  • Cash, cash equivalents and restricted cash totaled USD 7.8 million, including about USD 3 million restricted under the Gates Foundation grant, with funding expected to last into late 2026.
  • Management expects higher R&D spending in coming quarters as it targets an IND or equivalent CTA filing in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-214816), on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.